Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Titel:
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Auteur:
Al-Batran, Salah-Eddin Hofheinz, Ralf D Pauligk, Claudia Kopp, Hans-Georg Haag, Georg Martin Luley, Kim Barbara Meiler, Johannes Homann, Nils Lorenzen, Sylvie Schmalenberg, Harald Probst, Stephan Koenigsmann, Michael Egger, Matthias Prasnikar, Nicole Caca, Karel Trojan, Jörg Martens, Uwe M Block, Andreas Fischbach, Wolfgang Mahlberg, Rolf Clemens, Michael Illerhaus, Gerald Zirlik, Katja Behringer, Dirk M Schmiegel, Wolff Pohl, Michael Heike, Michael Ronellenfitsch, Ulrich Schuler, Martin Bechstein, Wolf O Königsrainer, Alfred Gaiser, Timo Schirmacher, Peter Hozaeel, Wael Reichart, Alexander Goetze, Thorsten O Sievert, Mark Jäger, Elke Mönig, Stefan Tannapfel, Andrea